Israeli -
Kiebrania -
Ministry of Health
ספרייסל 70 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
Israeli -
Kiebrania -
Ministry of Health
ספרייסל 100 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib
Israeli -
Kiebrania -
Ministry of Health
ספרייסל 20 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 20 mg - dasatinib
Israeli -
Kiebrania -
Ministry of Health
ספרייסל 50 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib
Israeli -
Kiebrania -
Ministry of Health
ספרייסל 70 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
Israeli -
Kiebrania -
Ministry of Health
סוטנט 12.5 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
Israeli -
Kiebrania -
Ministry of Health
סוטנט 25 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
Israeli -
Kiebrania -
Ministry of Health
סוטנט 50 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
Israeli -
Kiebrania -
Ministry of Health
טסיגנה 200 מג
novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Israeli -
Kiebrania -
Ministry of Health
סטיוורגה
bayer israel ltd - regorafenib - טבליות מצופות פילם - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and if kras wild-type, an anti-egfr therapy.for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate